Potent inhibition of TGF-β signaling pathway regulator Abl: potential therapeutics for hepatic fibrosis

Referencess

• Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209–18
   PubMed Web of Science ®Google Scholar
• Jiao J, Friedman SL, Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009;25:223–9
   PubMed Web of Science ®Google Scholar
• Lotersztajn S, Julien B, Teixeira-Clerc F, et al. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2005;45:605–28
   PubMed Web of Science ®Google Scholar
• Cong M, Iwaisako K, Jiang C, Kisseleva T. Cell signals influencing hepatic fibrosis. Int J Hepatol 2012;2012:158547
   Google Scholar
• Distler JH, Distler O. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology 2008;47:10–1
   PubMed Web of Science ®Google Scholar
• Distler JH, Distler O. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann Rheum Dis 2010;69:i48–51
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang Z, Kwong SQ, et al. Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist nilotinib. J Hepatol 2011;55:12–625
   Web of Science ®Google Scholar
• Zhou P, Wang C, Ren Y, et al. Computational peptidology: a new and promising approach to therapeutic peptide design. Curr Med Chem 2013;20:1985–96
   PubMed Web of Science ®Google Scholar
• Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008;36:D901–6
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3–26
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:235–42
   PubMed Web of Science ®Google Scholar
• Liu T, Lin Y, Wen X, et al. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 2007;35:D198–201
   PubMed Web of Science ®Google Scholar
• Wang R, Fang X, Lu Y, Wang S. The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. J Med Chem 2004;47:2977–80
   PubMed Web of Science ®Google Scholar
• Hu L, Benson ML, Smith RD, et al. Binding MOAD (Mother Of All Databases). Proteins 2005;60:333–40
   PubMed Web of Science ®Google Scholar
• Mysinger MM, Shoichet BK. Rapid context-dependent ligand desolvation in molecular docking. J Chem Inf Model 2010;50:1561–73
   PubMed Web of Science ®Google Scholar
• Cornell WD, Cieplak P, Bayly CI, et al. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 1995;117:5179–97
   Web of Science ®Google Scholar
• Weiss DR, Ahn S, Sassano MF, et al. Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptor. ACS Chem Biol 2013;8:1018–26
   PubMed Web of Science ®Google Scholar
• Meng EC, Shoichet BK, Kuntz ID. Automated docking with grid-based energy evaluation. J Comput Chem 1992;13:505–24
   Web of Science ®Google Scholar
• Huang SY, Grinter SZ, Zou X. Scoring functions and their evaluation methods for protein–ligand docking: recent advances and future directions. Phys Chem Chem Phys 2010;12:12899–908
   PubMed Web of Science ®Google Scholar
• Case DA, Cheatham TE, Darden T, et al. The Amber biomolecular simulation programs. J Comput Chem 2005;26:1668–88
   PubMed Web of Science ®Google Scholar
• Hou T, Yu R. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance. J Med Chem 2007;50:1177–88
   PubMed Web of Science ®Google Scholar
• Darden T, York D, Pedersen L. Particle mesh Ewald and N.log(N) method for Ewald sums in large systems. J Chem Phys 1993;98:10089–92
   Web of Science ®Google Scholar
• Ryckaert J, Ciccotti G, Berendsen HJC. Numerical-integration of Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 1977;23:327–41
   Web of Science ®Google Scholar
• Wang J, Wolf RM, Caldwell JW, et al. Developing and testing of a general amber force field. J Comput Chem 2004;25:1157–74
   PubMed Web of Science ®Google Scholar
• Jorgensen WL, Chandrasekhar J, Madura JD, et al. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983;79:926–35
   Web of Science ®Google Scholar
• Hou T, Zhang W, Wang J, Wang W. Predicting drug resistance of the HIV-1 protease using molecular interaction energy components. Proteins 2009;74:837–46
   PubMed Web of Science ®Google Scholar
• Glaser KB, Li J, Marcotte PA, et al. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther 2012;343:617–27
   PubMed Web of Science ®Google Scholar
• Jing T, Feng J, Li D, et al. Rational design of angiotensin-I-converting enzyme inhibitory peptides by integrating in silico modeling and an in vitro assay. ChemMedChem 2013;8:1057–66
   PubMed Web of Science ®Google Scholar
• Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein–ligand interactions. Protein Eng 1995;8:127–34
   PubMedGoogle Scholar
• Zhou P, Zou J, Tian F, Shang Z. Fluorine bonding – how does it work in protein–ligand interactions? J Chem Inf Model 2009;49:2344–55
   PubMed Web of Science ®Google Scholar
• Zhou P, Huang J, Tian F. Specific noncovalent interactions at protein–ligand interface: implications for rational drug design. Curr Med Chem 2012;19:226–38
   PubMed Web of Science ®Google Scholar